Pharma Co. Amarin Beats Class Action Over Patent Issues

By Katryna Perera · September 27, 2024, 6:44 PM EDT

A New Jersey federal judge has tossed a proposed class action against pharmaceutical company Amarin and its top brass, alleging they misled shareholders about their products and the prospects of related...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

DANG v. AMARIN CORPORATION PLC et al

Case Number

Court

New Jersey

Nature of Suit

Securities/Commodities

Date Filed

October 21, 2021

Recent Articles By Katryna

September 26, 2024
Healthcare REIT Defeats Investor Suit For Good
September 23, 2024
Mallinckrodt Brass Can't Avoid Investor Suit Over 2nd Ch. 11
September 23, 2024
SEC Scores $12M Judgment In Unregistered Dealer Case
September 05, 2024
Pharma Co. Verrica Fails To Shed Investor Suit Over FDA OK
August 21, 2024
Health Co. Investors Fight To Keep Suit Over Migrant Deal
August 06, 2024
Pharma Co. Founder Beats Suit Over Short-Swing Trading
August 05, 2024
Indivior Accused Of Overstating Prospects Of 3 Opioid Drugs
August 05, 2024
Centessa Beats Shareholder Suit Over Kidney Drug
July 30, 2024
Judge Wants Device Warning Answers From Mich. Justices
July 16, 2024
Drugmaker BioLineRx Beats Investor Suit Over Cash Shortfall